题图 | Pixabay文源 | 药研网2024年10月10日，FDA批准罗氏旗下基因泰克（Genentech）公司开发的口服小分子疗法Inavolisib ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

A new breast cancer drug has received quick federal approval after a clinical trial showed it could more than double the time before a common type of breast cancer recurrence worsens.

Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer, under the ...

周一，H.C. Wainwright维持对Relay Therapeutics（NASDAQ:RLAY）股票的买入评级，目标价保持在$19.00。该公司的背书紧随美国食品和药物管理局（FDA）最近批准罗氏公司的Itovebi（inavolisib）用于特定乳腺癌治疗之后。 这一批准意义重大，因为它基于第三期INAVO120试验的结果。该试验表明，Itovebi与Ibrance（palbocicli ...

With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K ...

Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its ...

Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...

Approval is based on Phase III INAVO120 results, showing the Itovebi™ (inavolisib)-based regimen more than doubled ...

As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...

Roche (RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of breast ...